Abdulrahman Ismaiel1,2, Dan L Dumitrascu1,2. 1. Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. 2. 2nd Department of Internal Medicine, Cluj-Napoca, Romania.
Abstract
BACKGROUND: Despite the demonstrated increased cardiovascular (CV) risk associated with metabolic-dysfunction-associated fatty liver disease (MAFLD), genetic variants predisposing to MAFLD were not constantly associated with CV events. Recently, rs641738C > T near membrane-bound O-acyltransferase domain-containing 7 (MBOAT7) has been studied in MAFLD and CV outcomes. Therefore, we aimed to evaluate the association between rs641738C > T in the presence and severity of hepatic steatosis, fibrosis, biochemical markers and progression to hepatocellular carcinoma (HCC), in addition to CV outcomes in MAFLD. MATERIALS AND METHODS: An electronic search on PubMed, Embase and Cochrane Library for articles published till 23 March 2020 was systematically performed. Articles were screened, and data extracted from eligible studies by two reviewers independently. RESULTS: Studies conducted on adults with MAFLD involving European, Hispanic and African American populations evaluating rs641738 reported reduced hepatic expression of MBOAT7, increased hepatic fat content, severity of MAFLD, susceptibility to develop NASH, advanced fibrosis and HCC in adults. However, most articles involving Asian individuals contradicted these findings. Studies involving obese children associated rs641738 with increased plasma alanine aminotransferase (ALT) levels, while its association with MAFLD remains inconsistent. The rs641738 variant was assessed as a MAFLD susceptibility gene in coronary artery disease (CAD) reporting neutral effects. CONCLUSIONS: Despite inconclusive results in Asian populations, rs641738C > T near MBOAT7 is associated with increased hepatic fat, MAFLD severity, susceptibility to develop NASH, advanced fibrosis and HCC in adults from Caucasian, Hispanic and African American ethnicities with MAFLD, as well as elevated ALT levels in children, while exerting neutral effects in CAD.
BACKGROUND: Despite the demonstrated increased cardiovascular (CV) risk associated with metabolic-dysfunction-associated fatty liver disease (MAFLD), genetic variants predisposing to MAFLD were not constantly associated with CV events. Recently, rs641738C > T near membrane-bound O-acyltransferase domain-containing 7 (MBOAT7) has been studied in MAFLD and CV outcomes. Therefore, we aimed to evaluate the association between rs641738C > T in the presence and severity of hepatic steatosis, fibrosis, biochemical markers and progression to hepatocellular carcinoma (HCC), in addition to CV outcomes in MAFLD. MATERIALS AND METHODS: An electronic search on PubMed, Embase and Cochrane Library for articles published till 23 March 2020 was systematically performed. Articles were screened, and data extracted from eligible studies by two reviewers independently. RESULTS: Studies conducted on adults with MAFLD involving European, Hispanic and African American populations evaluating rs641738 reported reduced hepatic expression of MBOAT7, increased hepatic fat content, severity of MAFLD, susceptibility to develop NASH, advanced fibrosis and HCC in adults. However, most articles involving Asian individuals contradicted these findings. Studies involving obesechildren associated rs641738 with increased plasma alanine aminotransferase (ALT) levels, while its association with MAFLD remains inconsistent. The rs641738 variant was assessed as a MAFLD susceptibility gene in coronary artery disease (CAD) reporting neutral effects. CONCLUSIONS: Despite inconclusive results in Asian populations, rs641738C > T near MBOAT7 is associated with increased hepatic fat, MAFLD severity, susceptibility to develop NASH, advanced fibrosis and HCC in adults from Caucasian, Hispanic and African American ethnicities with MAFLD, as well as elevated ALT levels in children, while exerting neutral effects in CAD.
Authors: Abimbola Adenote; Igor Dumic; Cristian Madrid; Christopher Barusya; Charles W Nordstrom; Libardo Rueda Prada Journal: Can J Gastroenterol Hepatol Date: 2021-04-15
Authors: J Samael Rodríguez-Sanabria; Rebeca Escutia-Gutiérrez; Rebeca Rosas-Campos; Juan S Armendáriz-Borunda; Ana Sandoval-Rodríguez Journal: Front Med (Lausanne) Date: 2022-01-11
Authors: Kevin Teo; Kushala W M Abeysekera; Leon Adams; Elmar Aigner; Quentin M Anstee; Jesus M Banales; Rajarshi Banerjee; Priyadarshi Basu; Thomas Berg; Pallav Bhatnagar; Stephan Buch; Ali Canbay; Sonia Caprio; Ankita Chatterjee; Yii-Der Ida Chen; Abhijit Chowdhury; Ann K Daly; Christian Datz; Dana de Gracia Hahn; Johanna K DiStefano; Jiawen Dong; Amedine Duret; Connor Emdin; Madison Fairey; Glenn S Gerhard; Xiuqing Guo; Jochen Hampe; Matthew Hickman; Lena Heintz; Christian Hudert; Harriet Hunter; Matt Kelly; Julia Kozlitina; Marcin Krawczyk; Frank Lammert; Claudia Langenberg; Joel Lavine; Lin Li; Hong Kai Lim; Rohit Loomba; Panu K Luukkonen; Phillip E Melton; Trevor A Mori; Nicholette D Palmer; Constantinos A Parisinos; Sreekumar G Pillai; Faiza Qayyum; Matthias C Reichert; Stefano Romeo; Jerome I Rotter; Yu Ri Im; Nicola Santoro; Clemens Schafmayer; Elizabeth K Speliotes; Stefan Stender; Felix Stickel; Christopher D Still; Pavel Strnad; Kent D Taylor; Anne Tybjærg-Hansen; Giuseppina Rosaria Umano; Mrudula Utukuri; Luca Valenti; Lynne E Wagenknecht; Nicholas J Wareham; Richard M Watanabe; Julia Wattacheril; Hanieh Yaghootkar; Hannele Yki-Järvinen; Kendra A Young; Jake P Mann Journal: J Hepatol Date: 2020-08-31 Impact factor: 25.083